Find a Clinical Trial

Showing 1 - 10 of 34 Trials

  • The Acceptability of a Rapid Esophageal Adenocarcinoma Risk Test (REACT)

    Principal Investigator:

    Julian Adin Abrams, MD

    Contact Number:

    (212) 342-5162

    NCT Number:

    NCT03366012

    Population:

    Adult

    Phase:

    NA
    This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing. The time of involvement for an individual will range from 2 weeks to 2 months, depending on the results of the Cytosponge test and time to follow up endoscopy, if indicated. The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the...

  • Phase 1 Study of the PKMYT1 Inhibitor RP-6306 inCombination With FOLFIRI for the Treatment of AdvancedSolid Tumors (MINOTAUR Study)

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05147350

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test how safe RP-6306 and FOLFIRI are when given together at different doses and on different schedules, and test how well RP-6306 and FOLFIRI work together to shrink solid tumors in the body. This is the first time RP-6306 is being given with FOLFIRI to humans. Are you Eligible? (Inclusion Criteria) ≥18 years old have locally advanced or metastatic CRC, GI, or esophageal cancer(s) Life expectancy ≥12 weeks able to swallow oral medications

  • Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04535401

    Population:

    Adult

    Phase:

    I
    This study is being done to answer the following question: What is the highest dose of BAY 1895344 and FOLFIRI chemotherapy (irinotecan, 5- fluorouracil, which is also known as 5-FU, and leucovorin) in combination that can be safely and tolerably taken in patients with advanced gastrointestinal cancer? This is the first time that these drugs will be tested together in humans. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your cancer. The usual approach is defined as care most people get for advanced gastrointestinal cancer...

  • A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinicalbenefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment ofparticipants with advanced and metastatic gastrointestinal cancer

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05104567

    Population:

    Adult

    Phase:

    II
    The purpose of this research study is to test the experimental drug, SAR444245, in combination with other anticancer therapies, cetuximab or pembrolizumab, for the treatment of advanced or metastatic gastrointestinal cancer. SAR444245 will also be combined with one anticancer therapy, pembrolizumab, that belongs to a class of therapies called immune checkpoint inhibitors (ICI- type of drug that blocks proteins called checkpoints that are made by immune system cells and some cancer cells) that is already approved for the treatment of these conditions. Investigational means that the drug has...

  • Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer​

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    (212) 342-5162

    NCT Number:

    NCT03674567

    Population:

    Adult

    Phase:

    I/II
    This study is designed to test different doses of FLX475 to see if it is safe and to study how the drug is absorbed and how the human body gets rid of the drug. The study will test FLX475 alone and in combination with pembrolizumab, a drug already approved by the United States Food and Drug Administration (FDA) for the treatment of patients with certain types of cancers. Pembrolizumab also works to stimulate your immune system and is also known as a checkpoint inhibitor. The objective of the study is to assess the safety and activity of FLX475 alone and FLX475 in combination with...

  • Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

    Principal Investigator:

    Bret Taback, MD

    Contact Number:

    (212) 342-5162

    NCT Number:

    NCT03857620

    Population:

    Adult

    Phase:

    NA
    Surgery is the main treatment for many cancer conditions. In many elderly patients, surgery can greatly affect physical condition, and the ability to return to pre-surgery levels of physical functioning. By providing some simple pre-surgical recommendations, it may be possible to improve the rate of recovery from surgery and the possibility that patients will return to their pre-surgery levels of function. Your doctors are participating in a study to determine if a change in how they evaluate and manage elderly patients will improve recovery rates from major cancer surgery. Doctors and...

  • A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in combination with cisplatin and with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma

    Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04491942

    Population:

    Adult

    Phase:

    I
    This study is being done to answer the following question: What is the highest dose of BAY 1895344 that can be given safely in combination with cisplatin and gemcitabine in patients with advanced solid tumors, including urothelial carcinoma? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced solid tumor or urothelial carcinoma. The usual approach is defined as care most people get for advanced solid tumors or urothelial carcinoma. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have...

  • A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors

    Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04895709

    Population:

    Adult

    Phase:

    I/II
    The main purpose of this study is to test the safety of the investigational drug, BMS-986340, administered alone and in combination with nivolumab. This study will investigate how patients with selected advanced solid tumors tolerate these drugs to identify the highest tolerable dose or the most suitable dose, explore any changes in your tumor, and your general health after receiving multiple doses of BMS-986340 alone or together with nivolumab. BMS-986340 is an immunotherapy antibody and an investigational research drug. Investigational drugs are drugs that are not yet approved by the Food...

  • Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2 Expressing Solid Tumors

    Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04278144

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to learn about the study drug BDC-1001 in patients with HER2-expressing tumors. Researchers will be studying the use of BDC-1001 alone as well as in combination with Pembrolizaumab. This study will help researchers learn if the study drug can help with HER2-expressing tumors and how people respond to the drug. The researchers of this study will be looking at the safety, efficiency, and tolerability of BDC-1001, as well as how the body absorbs, breaks down, and removes the drug in patients with advanced HER2-expressing solid tumors. This research study will be the...

  • An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03639714

    Population:

    Adult

    Phase:

    I/II
    The purpose of this research study is to learn more about an experimental personalized vaccine that has two components called GRT-C901 and GRT-R902. We will learn more about the effects of this vaccine on your cancer when used together with approved medications that activate the immune system, nivolumab (Opdivo) as well as ipilimumab (Yervoy), which are approved by the United States Food and Drug Administration (FDA). The vaccine is specific to you and your tumor, and cannot be used to treat any other patients. Are you Eligible? (Inclusion Criteria) Do you have bladder, colon stomach, lung,...

Pages